Relmada Therapeutics (RLMD) Net Cash Flow (2012 - 2026)

Relmada Therapeutics (RLMD) has reported Net Cash Flow for 15 consecutive years, with $6.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Cash Flow rose 331.96% year-over-year to $6.3 million; the TTM figure through Mar 2026 stood at $8.7 million (up 4794.63% YoY), while the FY2025 annual figure was -$360486.0, down 53.7% from the prior year.
• Net Cash Flow rose to $6.3 million in Q1 2026 per RLMD's latest filing, from $2.1 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $23.5 million in Q1 2023 and bottomed at -$37.1 million in Q4 2022.
• Historically, Net Cash Flow has averaged -$2.0 million across 5 years, with a median of $31133.0 in 2025.
• Annual changes were most pronounced in 2022 — Net Cash Flow slumped 986.8% — and 2023, when it jumped 4686.45%.
• Relmada Therapeutics' Net Cash Flow stood at -$37.1 million in 2022, then soared by 93.24% to -$2.5 million in 2023, then soared by 194.61% to $2.4 million in 2024, then slipped by 11.01% to $2.1 million in 2025, then jumped by 197.33% to $6.3 million in 2026.
• Business Quant data shows RLMD's Net Cash Flow at $6.3 million in Q1 2026, $2.1 million in Q4 2025, and $31133.0 in Q3 2025.